Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Oct 2:46:101923.
doi: 10.1016/j.rmcr.2023.101923. eCollection 2023.

Improvement in the clinical manifestations of interstitial lung disease following treatment with placental mesenchymal stromal cell extracellular vesicles in a patient with systemic sclerosis: A case report

Shirin Assar  1   2 , Dena Mohammadzadeh  2 , Amir Hossein Norooznezhad  1 , Mehrdad Payandeh  2 , Daryoush Hassaninia  2 , Mehran Pournazari  2 , Parviz Soufivand  2 , Reza Yarani  1 , Kamran Mansouri  1
Affiliations
Case Reports

Improvement in the clinical manifestations of interstitial lung disease following treatment with placental mesenchymal stromal cell extracellular vesicles in a patient with systemic sclerosis: A case report

Shirin Assar et al. Respir Med Case Rep. .

Abstract

Background: Interstitial lung disease (ILD) is a severe systemic sclerosis (SSc) complication with no current approved or golden standard treatment. This report aims to investigate the effectiveness of treatment with placental mesenchymal stromal cell (MSC) extracellular vesicles (EVs) in a patient with ILD due to SSc.

Case presentation: The patient was a 55-year-old woman with a ten years history of SSc complicated by severe ILD. Over time, her lung disease progressed to interstitial fibrosis despite being treated with mycophenolate mofetil and monthly pulses of cyclophosphamide. Thus, she was treated with eight doses of placenta MSC-EVs. Four weeks after the third dose (Day 31 after the first dose), she reported marked improvement in her clinical symptoms, such as dyspnea and cough. Also, chest computed tomography (CT) scans demonstrated a significant reduction in ground glass consolidations and fibrotic changes. The patient was subsequently followed for twelve months, with findings showing significant improvement in exercise tolerance and reduced supplemental oxygen need.

Conclusion: In this single case, placental MSC-EVs were seen to provide a potentially efficient treatment for SSc-related ILD; however, further investigation and clinical trials are necessary.

Keywords: Extracellular vesicles; Interstitial lung disease; Mesenchymal stromal cells; Systemic sclerosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Chest computed tomography (CT) scan before the intervention showed diffuse ground-glass consolidations with sub-pleural reticulations and fibrotic changes.
Fig. 2
Fig. 2
Chest computed tomography (CT) scan after the intervention showed a significant reduction in ground glass consolidations and fibrotic changes.
See this image and copyright information in PMC

References

    1. Gabrielli A., Avvedimento E.V., Krieg T. Scleroderma. N. Engl. J. Med. 2009;360(19):1989–2003. doi: 10.1056/NEJMra0806188. - DOI - PubMed
    1. Vonk M.C., Smith V., Sfikakis P.P., Cutolo M., Del Galdo F., Seibold J.R. Pharmacological treatments for SSc-ILD: systematic review and critical appraisal of the evidence. Autoimmun. Rev. 2021;20(12) doi: 10.1016/j.autrev.2021.102978. - DOI - PubMed
    1. Colletti M., Galardi A., De Santis M., Guidelli G.M., Di Giannatale A., Di Luigi L., et al. Exosomes in systemic sclerosis: messengers between immune, vascular and fibrotic components? Int. J. Mol. Sci. 2019;20(18):4337. doi: 10.3390/ijms20184337. - DOI - PMC - PubMed
    1. Maria A.T., Toupet K., Maumus M., Fonteneau G., Le Quellec A., Jorgensen C., et al. Human adipose mesenchymal stem cells as potent anti-fibrosis therapy for systemic sclerosis. J. Autoimmun. 2016;70:31–39. doi: 10.1016/j.jaut.2016.03.013. - DOI - PubMed
    1. Rozier P., Maumus M., Maria A.T.J., Toupet K., Lai-Kee-Him J., Jorgensen C., et al. Mesenchymal stromal cells-derived extracellular vesicles alleviate systemic sclerosis via miR-29a-3p. J. Autoimmun. 2021;121 doi: 10.1016/j.jaut.2021.102660. - DOI - PubMed

Publication types

LinkOut - more resources